Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Climb 4.7% – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price was up 4.7% on Tuesday. The company traded as high as $4.00 and last traded at $3.8750. Approximately 10,114,293 shares changed hands during mid-day trading, a decline of 45% from the average daily volume of 18,239,877 shares. The stock had previously closed at $3.70.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on RXRX shares. Wall Street Zen upgraded Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 29th. Morgan Stanley set a $5.30 price target on Recursion Pharmaceuticals in a report on Monday, August 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of “Hold” and an average price target of $8.06.

Recursion Pharmaceuticals Stock Up 4.2%

The stock has a market cap of $2.06 billion, a price-to-earnings ratio of -3.71 and a beta of 1.07. The firm has a 50 day simple moving average of $3.34 and a two-hundred day simple moving average of $3.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 5.03.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). The firm had revenue of $7.67 million during the quarter, compared to analyst estimates of $10.97 million. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. During the same quarter in the prior year, the business earned ($0.41) earnings per share. As a group, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -0.94 EPS for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $3.96, for a total transaction of $158,400.00. Following the transaction, the director directly owned 6,218,287 shares in the company, valued at approximately $24,624,416.52. The trade was a 0.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 22,408 shares of the stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total value of $78,876.16. Following the completion of the sale, the chief executive officer owned 2,072,890 shares of the company’s stock, valued at $7,296,572.80. This trade represents a 1.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 122,408 shares of company stock valued at $434,976 in the last three months. 6.65% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of RXRX. MCF Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals in the second quarter valued at approximately $27,000. Integral Investment Advisors Inc. bought a new stake in Recursion Pharmaceuticals in the 1st quarter valued at $39,000. MQS Management LLC acquired a new position in Recursion Pharmaceuticals in the 1st quarter worth $41,000. Fund Advisors of America Inc FL acquired a new position in Recursion Pharmaceuticals in the 2nd quarter worth $45,000. Finally, QRG Capital Management Inc. bought a new position in Recursion Pharmaceuticals during the 1st quarter worth about $47,000. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biotechnology company that uses artificial intelligence, automation, and large-scale biological experimentation to accelerate the discovery and development of medicines. Its technology platform, known as the Recursion Operating System, integrates data from biology, chemistry, imaging, and machine learning to identify potential drug candidates and better understand disease biology.

The company develops therapies for areas including oncology, rare diseases, and neurological disorders.